Intellia Therapeutics Inc Stock
We can see a decrease in the price for Intellia Therapeutics Inc. Compared to yesterday it has lost -€0.120 (-1.090%).
Currently there is a rather positive sentiment for Intellia Therapeutics Inc with 22 Buy predictions and 7 Sell predictions.
With a target price of 25 € there is potential for a 126.35% increase which would mean more than doubling the current price of 11.05 € for Intellia Therapeutics Inc.
Our community identified positive and negative aspects for Intellia Therapeutics Inc stock for the coming years. 4 users see the criterium "Worthwhile Investment for the next years" as a plus for the Intellia Therapeutics Inc stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Intellia Therapeutics Inc in the next few years
Pros
?
G***** c******* t* c**********
?
M***** P*******
?
C******** o* t** e**********
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Intellia Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Intellia Therapeutics Inc | -1.090% | -5.795% | 40.256% | 11.240% | 41.622% | -72.941% | -81.167% |
| Chromadex Corp | -0.980% | -6.667% | -7.547% | -9.259% | -10.909% | 163.441% | 25.641% |
| Polynovo Ltd | 1.800% | -6.504% | -16.058% | -52.479% | -15.441% | -64.939% | -64.506% |
| Cardio3 Biosciences S.A. | -0.380% | -1.873% | 0.769% | -68.010% | -2.963% | -89.209% | -98.085% |
Comments
Intellia Therapeutics (NASDAQ:NTLA) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Show more
Ratings data for NTLA provided by MarketBeat
News
Intellia CEO Sells $314K in Stock While Holding Over 1 Million Shares
On Jan. 5, John M. Leonard, the president and CEO of Intellia Therapeutics (NASDAQ:NTLA), executed an open-market sale of 34,146 directly held shares, totaling $314,484.66, as disclosed in a SEC
2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street
Intellia Therapeutics (NASDAQ: NTLA) and Iovance Biotherapeutics (NASDAQ: IOVA) are relatively innovative biotech companies. However, due to company-specific headwinds, both have seen their shares
2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street
The "Magnificent Seven" stocks, a group of (mostly) tech giants, are among the most covered companies on Wall Street. The general sentiment about these corporations is that they boast attractive